Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) enables precise genome editing, allowing researchers to accurately explore gene function. In Alzheimer’s disease (AD) research, knocking out specific genes in myeloid cells — key players in neuroinflammation — helps scientists uncover potential therapeutic targets. In this webinar, Heyne Cecilia Lee will discuss the role of CRISPR-Cas9 in early drug discovery, highlighting how CRISPR-based knockouts in myeloid cells are shaping the future of AD therapeutics.
Topics to be covered:
- The role of CRISPR-Cas9 in early drug discovery efforts, such as target validation
- How to generate gene knockouts in myeloid cells
- How to target microglial pathways for developing AD treatments
Wednesday, April 30th, 2025 | 11:00 AM - 12:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
Heyne Cecilia Lee, PhD
Senior Scientist
AbbVie Deutschland GmbH & Co. KG
Melanie Homberg, PhD
Global Market Development Manager
Lonza
